Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:2898-2905
Published online before print May 31, 2005, doi: 10.1161/CIRCULATIONAHA.104.526673
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
111/22/2898    most recent
CIRCULATIONAHA.104.526673v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sweeney, M. O.
Right arrow Articles by Stark, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sweeney, M. O.
Right arrow Articles by Stark, A. J.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Pacemakers and Implantable Defibrillators
Related Collections
Right arrow Primary prevention
Right arrow Secondary prevention
Right arrow Ablation/ICD/surgery
Right arrow Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2005;111:2898-2905.)
© 2005 American Heart Association, Inc.


Arrhythmia/Electrophysiology

Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients

Results From the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) Trial

Michael O. Sweeney, MD; Mark S. Wathen, MD; Kent Volosin, MD; Ismaile Abdalla, MD; Paul J. DeGroot, MS; Mary F. Otterness, MS; Alice J. Stark, RN, PhD

From Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (M.O.S.); Vanderbilt University Medical Center, Nashville, Tenn (M.S.W.); University of Pennsylvania, Philadelphia, Pa (K.V.); Amarillo Heart Group, Amarillo, Tex (I.A.); and Medtronic, Inc, Minneapolis, Minn (P.J.D., M.F.O., A.J.S.).

Correspondence to Michael O. Sweeney, MD, Cardiac Arrhythmia Service, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail mosweeney{at}partners.org

Received November 30, 2004; revision received February 3, 2005; accepted March 1, 2005.

Background— Implantable cardioverter defibrillators (ICDs) reduce mortality in primary and secondary prevention. Quality of life, mortality, appropriate therapies for specific ventricular rhythms, and inappropriate therapies for supraventricular tachycardia (SVT) were compared among 582 patients (primary prevention=248; secondary prevention=334) in PainFREE Rx II, a 634-patient prospective, randomized study of antitachycardia pacing or shocks for fast ventricular tachycardia (FVT).

Methods and Results— ICDs were programmed identically with 3 zones (ventricular tachycardia [VT] <188 bpm; FVT=188 to 250 bpm; ventricular fibrillation [VF] >250 bpm) but randomized to antitachycardia pacing or shock as initial therapy for FVT. All treated episodes with electrograms were adjudicated. Primary prevention patients had lower ejection fractions and more coronary artery disease. ß-Blocker use, antiarrhythmic drug use, and follow-up duration were similar. Over 11±3 months, 1563 treated episodes were classified as VT (n=740), FVT (n=350), VF (n=77), and SVT (n=396). The distribution of VT, FVT, and VF was not different between primary and secondary prevention patients (respectively, VT 52% versus 54%, FVT 35% versus 35%, and VF 14% versus 10%). More secondary prevention patients had appropriate therapies (26% versus 18%, P=0.02), but among these patients, the median number of episodes per patient was similar. Inappropriate therapies occurred in 15% of both groups and accounted for similar proportions of all detected and treated episodes (46% in primary prevention patients versus 34% in secondary prevention patients, P=0.09). Quality of life improved modestly in both groups, and mortality was similar.

Conclusions— Primary prevention patients are slightly less likely to have appropriate therapies than secondary prevention patients, but episode density is similar among patients with appropriate therapies. SVT resulted in more than one third of therapies in both groups, but quality of life and mortality were similar.


Key Words: death, sudden • mortality • defibrillators, implantable • tachycardia, ventricular • tachycardia, supraventricular




This article has been cited by other articles:


Home page
Eur Heart JHome page
C. Leclercq, C. Daubert, and P. Mabo
Not too late, not too fast!!
Eur. Heart J., November 2, 2009; 30(22): 2689 - 2692.
[Full Text] [PDF]


Home page
EuropaceHome page
M. Gasparini, F. Regoli, P. Galimberti, C. Ceriotti, and A. Cappelleri
Cardiac resynchronization therapy in heart failure patients with atrial fibrillation
Europace, November 1, 2009; 11(suppl_5): v82 - v86.
[Abstract] [Full Text] [PDF]


Home page
Circ Arrhythm ElectrophysiolHome page
C. J. W. Borleffs, R. W.C. Scherptong, S.-C. Man, G. H. van Welsenes, J. J. Bax, L. van Erven, C. A. Swenne, and M. J. Schalij
Predicting Ventricular Arrhythmias in Patients With Ischemic Heart Disease: Clinical Application of the ECG-Derived QRS-T Angle
Circ Arrhythm Electrophysiol, October 1, 2009; 2(5): 548 - 554.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. C. van den Broek, I. Nyklicek, P. H. van der Voort, M. Alings, A. Meijer, and J. Denollet
Risk of ventricular arrhythmia after implantable defibrillator treatment in anxious type D patients.
J. Am. Coll. Cardiol., August 4, 2009; 54(6): 531 - 537.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
Task force members, J. Vijgen, G. Botto, J. Camm, C.-J. Hoijer, W. Jung, J.-Y. Le Heuzey, A. Lubinski, T. M. Norekval, M. Santomauro, et al.
Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators
Europace, August 1, 2009; 11(8): 1097 - 1107.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C. J. W. Borleffs, L. van Erven, M. Schotman, E. Boersma, P. Kies, A. E. B. van der Burg, K. Zeppenfeld, M. Bootsma, E. E. van der Wall, J. J. Bax, et al.
Recurrence of ventricular arrhythmias in ischaemic secondary prevention implantable cardioverter defibrillator recipients: long-term follow-up of the Leiden out-of-hospital cardiac arrest study (LOHCAT)
Eur. Heart J., July 1, 2009; 30(13): 1621 - 1626.
[Abstract] [Full Text] [PDF]


Home page
Circ Arrhythm ElectrophysiolHome page
M. M. Gulizia, L. Piraino, M. Scherillo, C. Puntrello, C. Vasco, M. C. Scianaro, F. Mascia, O. Pensabene, S. Giglia, G. Chiaranda, et al.
A Randomized Study to Compare Ramp Versus Burst Antitachycardia Pacing Therapies to Treat Fast Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter Defibrillators: The PITAGORA ICD Trial
Circ Arrhythm Electrophysiol, April 1, 2009; 2(2): 146 - 153.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
S. Tzeis, G. Andrikopoulos, C. Kolb, and P. E. Vardas
Tools and strategies for the reduction of inappropriate implantable cardioverter defibrillator shocks
Europace, November 1, 2008; 10(11): 1256 - 1265.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
M. Biffi, M. Ziacchi, M. Bertini, D. Sangiorgi, D. Corsini, C. Martignani, I. Diemberger, and G. Boriani
Longevity of implantable cardioverter-defibrillators: implications for clinical practice and health care systems
Europace, November 1, 2008; 10(11): 1288 - 1295.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
D. A.M.J. Theuns, M. Rivero-Ayerza, D. M. Goedhart, M. Miltenburg, and L. J. Jordaens
Morphology discrimination in implantable cardioverter-defibrillators: consistency of template match percentage during atrial tachyarrhythmias at different heart rates
Europace, September 1, 2008; 10(9): 1060 - 1066.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. L. Wilkoff, B. D. Williamson, R. S. Stern, S. L. Moore, F. Lu, S. W. Lee, U. M. Birgersdotter-Green, M. S. Wathen, I. C. Van Gelder, B. M. Heubner, et al.
Strategic Programming of Detection and Therapy Parameters in Implantable Cardioverter-Defibrillators Reduces Shocks in Primary Prevention Patients: Results From the PREPARE (Primary Prevention Parameters Evaluation) Study
J. Am. Coll. Cardiol., August 12, 2008; 52(7): 541 - 550.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
S. P. Bhavnani, C. I. Coleman, C. M. White, C. A. Clyne, R. Yarlagadda, D. Guertin, and J. Kluger
Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy
Europace, July 1, 2008; 10(7): 854 - 859.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, D. L. Hayes, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., May 27, 2008; 51(21): e1 - e62.
[Full Text] [PDF]


Home page
CirculationHome page
Writing Committee Members, A. E. Epstein, J. P. DiMarco, K. A. Ellenbogen, N.A. M. Estes III, R. A. Freedman, L. S. Gettes, A. M. Gillinov, G. Gregoratos, S. C. Hammill, et al.
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons
Circulation, May 27, 2008; 117(21): e350 - e408.
[Full Text] [PDF]


Home page
EuropaceHome page
J. B. Johansen, S. S. Pedersen, H. Spindler, K. Andersen, J. C. Nielsen, and P. T. Mortensen
Symptomatic heart failure is the most important clinical correlate of impaired quality of life, anxiety, and depression in implantable cardioverter-defibrillator patients: a single-centre, cross-sectional study in 610 patients
Europace, May 1, 2008; 10(5): 545 - 551.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. P. Daubert, W. Zareba, D. S. Cannom, S. McNitt, S. Z. Rosero, P. Wang, C. Schuger, J. S. Steinberg, S. L. Higgins, D. J. Wilber, et al.
Inappropriate Implantable Cardioverter-Defibrillator Shocks in MADIT II: Frequency, Mechanisms, Predictors, and Survival Impact
J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1357 - 1365.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
S. S Pedersen, D. A. Theuns, A. Muskens-Heemskerk, R. A. Erdman, and L. Jordaens
Type-D personality but not implantable cardioverter-defibrillator indication is associated with impaired health-related quality of life 3 months post-implantation
Europace, August 1, 2007; 9(8): 675 - 680.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
P. J. Zimetbaum
A 59-Year-Old Man Considering Implantation of a Cardiac Defibrillator
JAMA, May 2, 2007; 297(17): 1909 - 1916.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. H. Schoenfeld
Contemporary Pacemaker and Defibrillator Device Therapy: Challenges Confronting the General Cardiologist
Circulation, February 6, 2007; 115(5): 638 - 653.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. Ypenburg, L. van Erven, G. B. Bleeker, J. J. Bax, M. Bootsma, M. C. Wijffels, E. E. van der Wall, and M. J. Schalij
Benefit of Combined Resynchronization and Defibrillator Therapy in Heart Failure Patients With and Without Ventricular Arrhythmias
J. Am. Coll. Cardiol., August 1, 2006; 48(3): 464 - 470.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. O. Sweeney
Overcoming the Defects of a Virtue: Dual-Chamber Versus Single-Chamber Detection Enhancements for Implantable Defibrillator Rhythm Diagnosis: The Detect Supraventricular Tachycardia Study
Circulation, June 27, 2006; 113(25): 2862 - 2864.
[Full Text] [PDF]